NEXCEDE
LOE ApproachingNDAORALFILM
Approved
Nov 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 7h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEXCEDE is an oral film formulation approved by Novartis in 2009 as a small-molecule NDA. The specific mechanism of action and therapeutic indication are not publicly documented in available sources. The product represents a formulation innovation in oral delivery technology.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting the commercial team may be transitioning from growth defense to LOE strategy and preparing for generic entry.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NEXCEDE currently has zero linked job openings, reflecting its mature lifecycle stage and approaching LOE. Career opportunities on this product are limited and will likely focus on managed decline, brand defense, and transition planning rather than growth or innovation.
Brand ManagerField Sales Representative
Worked on NEXCEDE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.